Japan to Subsidize Sony's Image Sensor Plant in Kumamoto with $380 Million 
Apple Wins ITC Ruling, Keeping Blood-Oxygen Feature on Apple Watch 
Australia Extends Fuel Sulphur Relaxation Amid Iran War Supply Disruptions 
John Ternus Signals Apple’s Future with Product-First AI Strategy 
Indian Refiners Use Yuan via ICICI Bank to Pay for Iranian Oil Under U.S. Sanctions Waiver 
Greg Abel Sells Berkshire Hathaway Stocks Managed by Former Investment Manager Todd Combs 
Apple Stock Dips as Tim Cook Steps Down, John Ternus Named Next CEO 
Elon Musk Faces French Probe Over X and Grok Amid Rising U.S.-EU Tensions 
Huawei Expands Vietnam Presence Through Strategic Partnership with SHB Bank 
Tesla's Terafab: AI Chip Factory Eyes Taiwan's Semiconductor Talent 
OpenAI's $20 Billion Cerebras Deal Signals Massive AI Infrastructure Push 
Polymarket Seeks $400M Funding Round, Targets $15B Valuation Amid Prediction Market Boom 
Chinese Robotics Stocks React as Humanoid Robot Marathon Sparks Competition Concerns 
Nidec Stock Rises After Accounting Probe Report Eases Delisting Concerns 
AEVEX Raises $320 Million in IPO Amid Surging Defense Sector Demand 
Indonesia and Toyota Explore $300M Bioethanol Investment to Boost Renewable Energy Goals 
NVIDIA Acquisition Rumors Dismissed by Morgan Stanley as Strategically Flawed 
STAMFORD, Conn., Feb. 28, 2017 -- Loxo Oncology, Inc. (Nasdaq:LOXO), a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers, will announce financial results for the fourth quarter and full year ended December 31, 2016 on March 7, 2017 before the NASDAQ market open.
The company will not be conducting a conference call in conjunction with this earnings release.
About Loxo Oncology
Loxo Oncology is a biopharmaceutical company innovating the development of highly selective medicines for patients with genetically defined cancers. Our pipeline focuses on cancers that are uniquely dependent on single gene abnormalities, such that a single drug has the potential to treat the cancer with dramatic effect. We believe that the most selective, purpose-built medicines have the highest probability of maximally inhibiting the intended target, thereby delivering best-in-class disease control and safety. Our management team seeks out experienced industry partners, world-class scientific advisors and innovative clinical-regulatory approaches to deliver new cancer therapies to patients as quickly and efficiently as possible. For more information, please visit the company's website at www.loxooncology.com.
Contacts for Loxo Oncology, Inc.
Company:
Jacob S. Van Naarden
Chief Business Officer
[email protected]
Investors:
Peter Rahmer
The Trout Group, LLC
646-378-2973
[email protected]
Media:
Dan Budwick
Pure Communications, Inc.
973-271-6085
[email protected]
